tiprankstipranks
Context Therapeutics, Inc. (CNTX)
NASDAQ:CNTX
US Market
CNTX
Context Therapeutics
RESEARCH TOOLSreports
Want to see CNTX full AI Analyst Report?

Context Therapeutics (CNTX) Stock News & Sentiment

248 Followers
Analyst Lifts Price Target and Reiterates Buy on Context Therapeutics’ Bispecific Pipeline Progress and Strengthened Financial Position
Premium
Ratings
Analyst Lifts Price Target and Reiterates Buy on Context Therapeutics’ Bispecific Pipeline Progress and Strengthened Financial Position
2d ago
CNTX
Analyst Charles Zhu Reiterates Buy on Context Therapeutics, Citing Favorable CT-202 License Economics and Key CTIM-76 Ovarian Cancer Catalyst
Premium
Ratings
Analyst Charles Zhu Reiterates Buy on Context Therapeutics, Citing Favorable CT-202 License Economics and Key CTIM-76 Ovarian Cancer Catalyst
3d ago
CNTX
Context Therapeutics Secures Full Rights to Antibody Assets
Premium
Company Announcements
Context Therapeutics Secures Full Rights to Antibody Assets
3d ago
8K
CNTX
Context Therapeutics Maintained at Buy as Advancing Clinical Pipeline and Upcoming Catalysts Support Unchanged $5 Price Target
Premium
Ratings
Context Therapeutics Maintained at Buy as Advancing Clinical Pipeline and Upcoming Catalysts Support Unchanged $5 Price Target
14d ago
CNTX
Context Therapeutics settles governance lawsuit with mootness fee
Premium
Company Announcements
Context Therapeutics settles governance lawsuit with mootness fee
20d ago
8K
CNTX
Buy Rating Reiterated on Context Therapeutics as CTIM-76 T-Cell Engager Progress Supports Unchanged $5 Price Target
Premium
Ratings
Buy Rating Reiterated on Context Therapeutics as CTIM-76 T-Cell Engager Progress Supports Unchanged $5 Price Target
22d ago
CNTX
Context Therapeutics: Anticipated CTIM-76 Ovarian Cancer Data as a Key Catalyst for CNTX Re-Rating
Premium
Ratings
Context Therapeutics: Anticipated CTIM-76 Ovarian Cancer Data as a Key Catalyst for CNTX Re-Rating
28d ago
CNTX
More CNTX News >

CNTX News on the Web

Analyst Lifts Price Target and Reiterates Buy on Context Therapeutics’ Bispecific Pipeline Progress and Strengthened Financial Position
TipRanks News
Bullish
Analysts’ Top Healthcare Picks: Boston Scientific (BSX), Context Therapeutics (CNTX)
TipRanks News
Neutral
Analyst Charles Zhu Reiterates Buy on Context Therapeutics, Citing Favorable CT-202 License Economics and Key CTIM-76 Ovarian Cancer Catalyst
TipRanks News
Bullish
Context Therapeutics Secures Full Rights to Antibody Assets
TipRanks News
Neutral
Context Therapeutics enters license agreement amendment with BioAtla
TipRanks News
Bullish
Analysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Context Therapeutics (CNTX)
TipRanks News
Bullish
Piper Sandler Sticks to Its Buy Rating for Context Therapeutics (CNTX)
TipRanks News
Bullish
Context Therapeutics (CNTX) Gets a Buy from Guggenheim
TipRanks News
Bullish

News Score - Last 7 Days

Very Positive
CNTX
Sector Average
Media Buzz
This Week5 articles
Weekly Average3 articles
News Sentiment
This Week99%
Sector Average77%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CNTX’s Media Buzz Sentiment?
5 articles about CNTX were published this week. In an average week, 3 articles are published.
    What is CNTX’s weekly average amount of articles?
    In an average week, 3 articles about CNTX are published.
      What is CNTX’s News Sentiment?
      99% of articles about CNTX were positive this week, compared to its sector average of 77%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        IMVTImmunovant
        ROIVRoivant Sciences
        PROKProKidney
        Showing the stocks with the most bullish news sentiment over the past week